Participated · Series C · Apr 2026

Adcendo is advancing a pipeline of first- and potential best-in-class antibody-drug conjugates, integrating novel targets and optimized linker-payload combinations. The company is progressing three ADC programs: ADCE-T02 (Tissue Factor) in a Phase I Tiffany-01 cohort expansion across multiple solid tumors, ADCE-D01 (uPARAP) in Phase 1 dose escalation and expansion for soft tissue sarcoma and other mesenchymal cancers, and ADCE-B05 (undisclosed target) in preclinical evaluation and planned dose escalation in squamous cell carcinomas. Founded in 2017, Adcendo is headquartered in Copenhagen with operations in Boston, Massachusetts, and is led by a team with extensive ADC development and commercialization experience. The recent $75 million Series C financing is intended to fund the programs through upcoming clinical milestones and data readouts. No revenue or other operating metrics were disclosed in the provided articles.

Led · Series C · Jan 2026

Soley Therapeutics leverages live human cells as biosensors, capturing thousands of time-resolved features and translating them with proprietary computer vision and AI into structured signatures that reveal novel druggable biology. Its fully automated, high-throughput platform can screen hundreds of thousands of compounds per week, accelerating hit identification, mechanistic insight, and molecule design. The company’s lead oncology program targets acute myeloid leukemia and is slated for an IND filing in 2026, while a second solid-tumor asset is entering IND-enabling studies. Beyond oncology, Soley is advancing stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases. Recent funding will also support continued scale-up of the platform, which combines Oracle Cloud Infrastructure, NVIDIA AI Enterprise, and NVIDIA Blackwell GPUs. Headquartered in South San Francisco, Soley positions itself as a science-first organization marrying foundational biology with state-of-the-art automation and AI to build a broad, first-in-class pipeline.

Participated · Series B · Dec 2025

Triana Biomedicines is a private biopharmaceutical company building a target-first, proximity-first discovery platform to design molecular glue degraders that induce or enhance the breakdown of disease-causing proteins. Powered by bespoke chemical libraries, high-resolution structural biology and deep mechanistic insights, the platform is aimed at cancer indications where current modalities fall short. Its lead candidate, TRI-611, selectively degrades anaplastic lymphoma kinase (ALK) variants and is being advanced toward clinical proof of concept in ALK-positive non-small cell lung cancer. The company plans to nominate a second clinical candidate in 2026 and to mature multiple additional programs from its pipeline. An oversubscribed $120 million Series B round has strengthened the balance sheet and is expected to fund TRI-611 through early clinical studies while expanding the broader portfolio. No revenue or patient data have been disclosed, reflecting the company’s preclinical stage. Headquarters and laboratory operations are located in Lexington, Massachusetts.

Participated · Equity · Nov 2025

Solve Therapeutics is a San Diego-based, clinical-stage biopharmaceutical company focused on creating best-in-class antibody-drug conjugates for solid tumor malignancies. Its proprietary CloakLink™ linker platform is engineered to lower ADC hydrophobicity, improve pharmacokinetics, enhance plasma stability, and reduce toxicity, thereby expanding the therapeutic index of ADCs. The lead assets, SLV-154 and SLV-324, are both in Phase 1 clinical trials and are paired with novel diagnostic tools to enable precision patient selection. Founded by executives behind VelosBio and Acerta Pharma, the company aims to integrate therapeutic and diagnostic development for a more personalized oncology approach. The new financing lifts the firm’s total capital raised to $321 million, following a $75 million round closed in December 2024. Proceeds will fund completion of Phase 1b studies for both lead programs and broaden operational capabilities as the pipeline advances toward later-stage trials.

Participated · Series A · Oct 2025

Adcytherix focuses on designing and developing highly selective antibody-drug conjugates that incorporate proprietary payloads aimed at improving efficacy, tolerability, and resistance profiles in oncology. Its lead candidate, ADCX-020, is progressing toward first-in-human studies, with IND and CTA filings targeted for the end of 2025. In parallel, the company is expanding a broader pipeline of differentiated ADCs that leverage its novel payload platform. Founded about 18 months ago and led by CEO and founder Jack Elands, the team draws on deep scientific and commercial expertise in the ADC field. The company positions itself as a European leader in next-generation ADC innovation, emphasizing precision targeting and payload differentiation. With the recent €105 million Series A financing, Adcytherix now has substantial resources to transition from preclinical research to clinical development. The new capital underpins both the advancement of ADCX-020 and the ongoing build-out of its proprietary ADC platform.